NSCLC Biomarkers: HER2, c-MET, KRAS & the Future of Lung Cancer Treatment

Описание: Dr. Stewart Yang discusses the evolving landscape of NSCLC biomarker testing, moving beyond genomics to protein-based and computational markers.
Key topics include:
The rise of HER2 and c-MET IHC testing for ADC therapies.
Actionability of tumor suppressor genes like STK11 and KEAP1.
Emerging KRAS mutation therapies (G12C, G12D).
The potential of computational pathology and AI in biomarker analysis.
Synthetic lethality targeting MTAP deletions.
Learn about the latest advancements in personalized medicine for non-small cell lung cancer and how these biomarkers are shaping treatment strategies.